Nature:Rv0081基因可能是肺结核病原体适应组织缺氧长期生存的机制

2013-07-27 Nature Nature

肺结核是一种特别能使人身体虚弱的病,部分原因是“结核分枝杆菌”病原体能够无症状地在宿主体内长久存在很多个月、甚至几十年时间。对超过45个“结核分枝杆菌”转录因子所做的一项ChIP-Seq基因组图谱分析,结合来自这些因子的系统性过度表达的表达数据,被用来在系统范围内重建决定分支杆菌耐久力的调控网络。该网络揭示了对组织缺氧的适应与脂质代谢(二者都被认为是肺结核发病的关键)之间的联系,同时这项研究还发现

肺结核是一种特别能使人身体虚弱的病,部分原因是“结核分枝杆菌”病原体能够无症状地在宿主体内长久存在很多个月、甚至几十年时间。对超过45个“结核分枝杆菌”转录因子所做的一项ChIP-Seq基因组图谱分析,结合来自这些因子的系统性过度表达的表达数据,被用来在系统范围内重建决定分支杆菌耐久力的调控网络。该网络揭示了对组织缺氧的适应与脂质代谢(二者都被认为是肺结核发病的关键)之间的联系,同时这项研究还发现以前未被研究过的转录因子Rv0081是该网络的一个调控枢纽。

英文摘要:

Nature   doi:10.1038/nature12337

The Mycobacterium tuberculosis regulatory network and hypoxia

James E. Galagan,Kyle Minch,Matthew Peterson,Anna Lyubetskaya,Elham Azizi,Linsday Sweet,Antonio Gomes,Tige Rustad,Gregory Dolganov,Irina Glotova,  Thomas Abeel, Chris Mahwinney,Adam D. Kennedy,  René Allard,William Brabant, Andrew Krueger,Suma Jaini,Brent Honda,Wen-Han Yu,Mark J. Hickey,  Jeremy Zucker,Christopher Garay,Brian Weiner,Peter Sisk,Christian Stolte et al.

We have taken the first steps towards a complete reconstruction of the Mycobacterium tuberculosis regulatory network based on ChIP-Seq and combined this reconstruction with system-wide profiling of messenger RNAs, proteins, metabolites and lipids during hypoxia and re-aeration. Adaptations to hypoxia are thought to have a prominent role in M. tuberculosis pathogenesis. Using ChIP-Seq combined with expression data from the induction of the same factors, we have reconstructed a draft regulatory network based on 50 transcription factors. This network model revealed a direct interconnection between the hypoxic response, lipid catabolism, lipid anabolism and the production of cell wall lipids. As a validation of this model, in response to oxygen availability we observe substantial alterations in lipid content and changes in gene expression and metabolites in corresponding metabolic pathways. The regulatory network reveals transcription factors underlying these changes, allows us to computationally predict expression changes, and indicates that Rv0081 is a regulatory hub.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1941711, encodeId=f4cd1941e118f, content=<a href='/topic/show?id=693b8228594' target=_blank style='color:#2F92EE;'>#肺结核病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82285, encryptionId=693b8228594, topicName=肺结核病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Sun Oct 20 14:48:00 CST 2013, time=2013-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990479, encodeId=3dac19904e96e, content=<a href='/topic/show?id=26e2e7723a1' target=_blank style='color:#2F92EE;'>#组织缺氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77723, encryptionId=26e2e7723a1, topicName=组织缺氧)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sat Sep 21 17:48:00 CST 2013, time=2013-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879598, encodeId=575818e959836, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Dec 01 10:48:00 CST 2013, time=2013-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253876, encodeId=050e12538e6f9, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510613, encodeId=0cc41510613fa, content=<a href='/topic/show?id=2efbe0807b1' target=_blank style='color:#2F92EE;'>#病原体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70807, encryptionId=2efbe0807b1, topicName=病原体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6c210226313, createdName=xue8605, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618288, encodeId=f051161828858, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1941711, encodeId=f4cd1941e118f, content=<a href='/topic/show?id=693b8228594' target=_blank style='color:#2F92EE;'>#肺结核病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82285, encryptionId=693b8228594, topicName=肺结核病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Sun Oct 20 14:48:00 CST 2013, time=2013-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990479, encodeId=3dac19904e96e, content=<a href='/topic/show?id=26e2e7723a1' target=_blank style='color:#2F92EE;'>#组织缺氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77723, encryptionId=26e2e7723a1, topicName=组织缺氧)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sat Sep 21 17:48:00 CST 2013, time=2013-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879598, encodeId=575818e959836, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Dec 01 10:48:00 CST 2013, time=2013-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253876, encodeId=050e12538e6f9, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510613, encodeId=0cc41510613fa, content=<a href='/topic/show?id=2efbe0807b1' target=_blank style='color:#2F92EE;'>#病原体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70807, encryptionId=2efbe0807b1, topicName=病原体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6c210226313, createdName=xue8605, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618288, encodeId=f051161828858, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1941711, encodeId=f4cd1941e118f, content=<a href='/topic/show?id=693b8228594' target=_blank style='color:#2F92EE;'>#肺结核病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82285, encryptionId=693b8228594, topicName=肺结核病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Sun Oct 20 14:48:00 CST 2013, time=2013-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990479, encodeId=3dac19904e96e, content=<a href='/topic/show?id=26e2e7723a1' target=_blank style='color:#2F92EE;'>#组织缺氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77723, encryptionId=26e2e7723a1, topicName=组织缺氧)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sat Sep 21 17:48:00 CST 2013, time=2013-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879598, encodeId=575818e959836, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Dec 01 10:48:00 CST 2013, time=2013-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253876, encodeId=050e12538e6f9, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510613, encodeId=0cc41510613fa, content=<a href='/topic/show?id=2efbe0807b1' target=_blank style='color:#2F92EE;'>#病原体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70807, encryptionId=2efbe0807b1, topicName=病原体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6c210226313, createdName=xue8605, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618288, encodeId=f051161828858, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=)]
    2013-12-01 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1941711, encodeId=f4cd1941e118f, content=<a href='/topic/show?id=693b8228594' target=_blank style='color:#2F92EE;'>#肺结核病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82285, encryptionId=693b8228594, topicName=肺结核病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Sun Oct 20 14:48:00 CST 2013, time=2013-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990479, encodeId=3dac19904e96e, content=<a href='/topic/show?id=26e2e7723a1' target=_blank style='color:#2F92EE;'>#组织缺氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77723, encryptionId=26e2e7723a1, topicName=组织缺氧)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sat Sep 21 17:48:00 CST 2013, time=2013-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879598, encodeId=575818e959836, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Dec 01 10:48:00 CST 2013, time=2013-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253876, encodeId=050e12538e6f9, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510613, encodeId=0cc41510613fa, content=<a href='/topic/show?id=2efbe0807b1' target=_blank style='color:#2F92EE;'>#病原体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70807, encryptionId=2efbe0807b1, topicName=病原体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6c210226313, createdName=xue8605, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618288, encodeId=f051161828858, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1941711, encodeId=f4cd1941e118f, content=<a href='/topic/show?id=693b8228594' target=_blank style='color:#2F92EE;'>#肺结核病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82285, encryptionId=693b8228594, topicName=肺结核病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Sun Oct 20 14:48:00 CST 2013, time=2013-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990479, encodeId=3dac19904e96e, content=<a href='/topic/show?id=26e2e7723a1' target=_blank style='color:#2F92EE;'>#组织缺氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77723, encryptionId=26e2e7723a1, topicName=组织缺氧)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sat Sep 21 17:48:00 CST 2013, time=2013-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879598, encodeId=575818e959836, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Dec 01 10:48:00 CST 2013, time=2013-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253876, encodeId=050e12538e6f9, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510613, encodeId=0cc41510613fa, content=<a href='/topic/show?id=2efbe0807b1' target=_blank style='color:#2F92EE;'>#病原体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70807, encryptionId=2efbe0807b1, topicName=病原体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6c210226313, createdName=xue8605, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618288, encodeId=f051161828858, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=)]
    2013-07-29 xue8605
  6. [GetPortalCommentsPageByObjectIdResponse(id=1941711, encodeId=f4cd1941e118f, content=<a href='/topic/show?id=693b8228594' target=_blank style='color:#2F92EE;'>#肺结核病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82285, encryptionId=693b8228594, topicName=肺结核病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Sun Oct 20 14:48:00 CST 2013, time=2013-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990479, encodeId=3dac19904e96e, content=<a href='/topic/show?id=26e2e7723a1' target=_blank style='color:#2F92EE;'>#组织缺氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77723, encryptionId=26e2e7723a1, topicName=组织缺氧)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sat Sep 21 17:48:00 CST 2013, time=2013-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879598, encodeId=575818e959836, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Dec 01 10:48:00 CST 2013, time=2013-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253876, encodeId=050e12538e6f9, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510613, encodeId=0cc41510613fa, content=<a href='/topic/show?id=2efbe0807b1' target=_blank style='color:#2F92EE;'>#病原体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70807, encryptionId=2efbe0807b1, topicName=病原体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6c210226313, createdName=xue8605, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618288, encodeId=f051161828858, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=)]

相关资讯

PNAS:维生素D有助于治疗肺结核

  英国研究人员近日在美国新一期《国家科学院院刊》上报告说,高剂量的维生素D补充剂能加速肺结核患者的康复过程。   英国玛丽女王大学研究人员将95名接受抗生素标准疗法的肺结核患者分为两组,第一组44人同时服用高剂量维生素D补充剂,另外51名患者服用安慰剂。8周后,维生素D组患者肺部清除结核杆菌的速度明显快于安慰剂组患者。   领导这项研究的阿德里安·马蒂诺指

NEJM:寻求抗击肺结核的新疗法

每年都有将近两百万人死于肺结核,肺结核目前在美国已经得到了有效控制,可是在世界上别的国家依然很严重。来自布莱根妇女医院的研究者表示,这种不均衡的健康状况应该迫使我们思考控制肺结核的新型方法了,研究者的研究论文刊登在了近日的国际杂志New England Journal of Medicine上。 Keshavjee医生表示,目前全球范围内缺少抵抗肺结核的方法,而且随着时间的延续,我们已经接受了这

Thorax:吸入型糖皮质激素增加肺结核的发病风险

吸入型糖皮质激素(ICS)的使用可降低肺部免疫力。在ICS使用者中肺结核(TB)的发病风险越来越受关注。对于各种呼吸系统疾病患者中,ICS的使用是否与肺结核发病风险之间存在关联。针对这种情况,来自韩国汉城国立大学医学院呼吸内科的LeeChang-Hoon博士等人进行了一项研究,研究结果发表于2013年6月8日的《胸部》(Thorax)杂志上。作者发现长期大剂量使用ICS的患者可能会增加肺结核的

Thorax:糖尿病患者肺结核防治形势严峻

  墨西哥一项前瞻性研究发现,随着全球糖尿病患病率的增加,有必要对这些糖尿病患者进行肺结核(TB)的预防和管理及评估相应的效应。同时患有两种病的患者有全球蔓延的潜在危险,提示TB管理的重要性。相关论文12月18日在线发表于《胸腔》(Thorax)杂志。   研究纳入了南墨西哥于1995年至2010年通过对痰标本进行流行病学、临床微生物学评估而确诊的TB患者,每年随访一次,以确定治疗转归、有

狂犬病肺结核报告死亡均创新高

  卫生部日前发布的9月全国疫情报告数据显示,当月全国(不含台港澳)法定报告传染病报告发病数再度较上月大幅度减少,总计报告发病数减少了47711例,但报告死亡数增加了277例。其中,艾滋病报告死亡突破1100例,狂犬病、肺结核报告死亡数达到了今年以来的最高。   根据卫生部通报,全国9月甲类传染病报告发病8例(鼠疫1例,霍乱7例),死亡1人(鼠疫患者)。乙类传染病报告发病数居前五位的病种依次为病

IJTLD:缩短结核治疗疗程并不可取

近日,来自英国医学研究委员会临床试验分会的Phillips等人认为相对于标准的6个月抗结核治疗方案来说,在治疗非空洞性肺结核时可以将治疗疗程缩短为4个月。其研究结果刊登在2013年6月份的国际肺结核与肺部疾病(The International Journal of Tuberculosis and Lung Disease)杂志上,但是香港卫生署结核与胸部疾病服务中心的Kwok-Chiu Cha